ATYR Valuation

aTyr Pharma Inc

Add to Watchlist

Advanced Chart

5.350

+0.4(8.081%)1D

Overview
Forecast
Valuation
Earnings

ATYR Relative Valuation

ATYR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATYR is overvalued; if below, it's undervalued.

Historical Valuation

aTyr Pharma Inc (ATYR) is now in the Fair zone, suggesting that its current forward PS ratio of 69.76 is considered Fairly compared with the five-year average of -2.69. The fair price of aTyr Pharma Inc (ATYR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.41

Fair

-6.79

Trailing

Forward

-6.25

EV/EBITDA

aTyr Pharma Inc. (ATYR) has a current EV/EBITDA of -6.25. The 5-year average EV/EBITDA is -1.29. The thresholds are as follows: Strongly Undervalued below -5.00, Undervalued between -5.00 and -3.15, Fairly Valued between 0.56 and -3.15, Overvalued between 0.56 and 2.41, and Strongly Overvalued above 2.41. The current Forward EV/EBITDA of -6.25 falls within the Strongly Undervalued range.

-6.18

EV/EBIT

aTyr Pharma Inc. (ATYR) has a current EV/EBIT of -6.18. The 5-year average EV/EBIT is -1.23. The thresholds are as follows: Strongly Undervalued below -4.68, Undervalued between -4.68 and -2.95, Fairly Valued between 0.50 and -2.95, Overvalued between 0.50 and 2.22, and Strongly Overvalued above 2.22. The current Forward EV/EBIT of -6.18 falls within the Strongly Undervalued range.

74.10

aTyr Pharma Inc. (ATYR) has a current PS of 74.10. The 5-year average PS is 478.04. The thresholds are as follows: Strongly Undervalued below -1532.14, Undervalued between -1532.14 and -527.05, Fairly Valued between 1483.13 and -527.05, Overvalued between 1483.13 and 2488.22, and Strongly Overvalued above 2488.22. The current Forward PS of 74.10 falls within the Historic Trend Line -Fairly Valued range.

-5.36

P/OCF

aTyr Pharma Inc. (ATYR) has a current P/OCF of -5.36. The 5-year average P/OCF is -2.55. The thresholds are as follows: Strongly Undervalued below -6.36, Undervalued between -6.36 and -4.46, Fairly Valued between -0.64 and -4.46, Overvalued between -0.64 and 1.26, and Strongly Overvalued above 1.26. The current Forward P/OCF of -5.36 falls within the Undervalued range.

-6.34

P/FCF

aTyr Pharma Inc. (ATYR) has a current P/FCF of -6.34. The 5-year average P/FCF is -1.91. The thresholds are as follows: Strongly Undervalued below -5.95, Undervalued between -5.95 and -3.93, Fairly Valued between 0.12 and -3.93, Overvalued between 0.12 and 2.14, and Strongly Overvalued above 2.14. The current Forward P/FCF of -6.34 falls within the Strongly Undervalued range.

aTyr Pharma Inc (ATYR) has a current Price-to-Book (P/B) ratio of 6.10. Compared to its 3-year average P/B ratio of 2.09 , the current P/B ratio is approximately 192.58% higher. Relative to its 5-year average P/B ratio of 1.85, the current P/B ratio is about 229.60% higher. aTyr Pharma Inc (ATYR) has a Forward Free Cash Flow (FCF) yield of approximately -12.19%. Compared to its 3-year average FCF yield of -38.29%, the current FCF yield is approximately -68.17% lower. Relative to its 5-year average FCF yield of -35.26% , the current FCF yield is about -65.44% lower.

6.14

P/B

Median3y

2.09

Median5y

1.85

-11.47

FCF Yield

Median3y

-38.29

Median5y

-35.26

Competitors Valuation Multiple

The average P/S ratio for ATYR's competitors is 30.66, providing a benchmark for relative valuation. aTyr Pharma Inc Corp (ATYR) exhibits a P/S ratio of 74.10, which is 141.68% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Emergent BioSolutions Inc

Eton Pharmaceuticals Inc

Cullinan Therapeutics Inc

70.61

483.82M

Performance Decomposition

Market capitalization of ATYR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATYR in the past 1 year is driven by Unknown.